Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 453,538
  • Shares Outstanding, K 93,513
  • Annual Sales, $ 144,390 K
  • Annual Income, $ -146,180 K
  • 60-Month Beta 0.63
  • Price/Sales 3.10
  • Price/Cash Flow N/A
  • Price/Book 3.14
Trade ATNX with:

Options Overview

Details
  • Implied Volatility 83.85%
  • Historical Volatility 45.73%
  • IV Percentile 19%
  • IV Rank 17.94%
  • IV High 246.55% on 02/18/21
  • IV Low 48.28% on 08/21/20
  • Put/Call Vol Ratio 0.15
  • Today's Volume 577
  • Volume Avg (30-Day) 645
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 29,256
  • Open Int (30-Day) 28,753

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.43
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +4.21%
on 05/26/21
5.27 -10.82%
on 06/09/21
+0.02 (+0.43%)
since 05/18/21
3-Month
3.66 +28.42%
on 05/04/21
5.75 -18.26%
on 05/05/21
-0.15 (-3.09%)
since 03/18/21
52-Week
3.66 +28.42%
on 05/04/21
15.24 -69.16%
on 09/08/20
-8.50 (-64.39%)
since 06/18/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached...

ATNX : 4.70 (-3.09%)
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

ATNX : 4.70 (-3.09%)
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review

The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.

OMER : 15.06 (+0.60%)
ADPT : 39.45 (-0.93%)
ATNX : 4.70 (-3.09%)
CDMO : 23.14 (-2.40%)
Athenex Announces Klisyri(R) (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

ATNX : 4.70 (-3.09%)
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

PALM BEACH,  Fla., /PRNewswire/ -- Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of...

TRIL : 9.81 (-1.21%)
TRIL.TO : 12.18 (-0.65%)
ONCY : 2.92 (+3.18%)
ONC.TO : 3.65 (+4.29%)
ATNX : 4.70 (-3.09%)
SEEL : 3.02 (-4.43%)
MRKR : 3.21 (-4.18%)
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

BMY : 66.47 (-0.45%)
AGEN : 5.26 (-1.13%)
ADPT : 39.45 (-0.93%)
ATNX : 4.70 (-3.09%)
Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases

Bayer (BAYRY) enters a strategic deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for addressing eye diseases.

REGN : 537.92 (+0.36%)
BAYRY : 15.7300 (-1.47%)
ADPT : 39.45 (-0.93%)
ATNX : 4.70 (-3.09%)
Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

-- Data presented by investigators from the Texas Children's Cancer Center

ATNX : 4.70 (-3.09%)
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 27.03% and 110.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 4.70 (-3.09%)
Athenex Provides First Quarter 2021 Corporate and Financial Update

Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May

ATNX : 4.70 (-3.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 4.98
1st Resistance Point 4.84
Last Price 4.70
1st Support Level 4.61
2nd Support Level 4.51
3rd Support Level 4.37

See More

52-Week High 15.24
Fibonacci 61.8% 10.82
Fibonacci 50% 9.45
Fibonacci 38.2% 8.08
Last Price 4.70
52-Week Low 3.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar